The novel antibody therapy market is expected to reach USD 2.4 billion in 2023 anticipated to grow at a CAGR of 36% during the forecast period 2022-2035.

Cancer persists as a prominent cause of worldwide mortality, and projections indicate a considerable increase in new cases by 2040. While conventional treatments such as chemotherapy and surgery have been pivotal, their limitations in advanced stages have prompted a shift toward exploring more targeted solutions. Emerging as a promising avenue are novel antibody therapies, specifically designed to selectively target and eliminate tumor cells. These therapies are available in diverse formats, bolstering their efficacy and precision in targeting affected cells, thereby exhibiting significant potential in multiple clinical trials as anti-cancer agents.
Six innovative antibody therapies?namely Adcetris?, Elzonris?, Lumoxiti?, Pluvicto?, Vicineum?, and Zevalin?have received approval for various oncological disorders. Additionally, more than 130 therapies are currently under evaluation at different stages. The realm of research in this field is expansive, involving over 50 companies and research institutions. Optimism surrounds the expectation of numerous promising treatments becoming accessible within the coming decade. The market for novel antibody therapies is characterized by substantial innovation, evident in the filing or granting of over 4,500 patents in recent times.
The advancement in this sector is propelled by collaborations between industry and academic stakeholders. Major pharmaceutical companies, along with emerging entities, contribute to further expanding the therapy pipeline. The ongoing positive clinical research and this momentum signify an anticipated steady growth in the novel antibody therapy market in the foreseeable future.

Report Coverage
? An executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the novel antibody therapies market in the mid to long term.
? A general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (Antibody-Directed Enzyme Prodrug Therapy, TCR like Antibodies, Radioisotope Immunoconjugates, Immunotoxins, Intracellular Antibody and Immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.
? An overview of the current market landscape of novel antibody therapies, such as immunocytokines, immunotoxins and radioisotopes immunoconjugates. In addition, the chapter includes a detailed analysis of these antibody therapies based on several relevant parameters. Immunocytokines have been analyzed based on status of development, mechanism of action, type of cytokine, type of antigen / format, dosing frequency type of therapy, mode of administration, route of administration, type of therapy and target disease indication(s).
? Detailed profiles of key players engaged in the development of novel antibody therapies. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
? Information on more than 550 completed, ongoing and planned clinical studies of novel antibody therapies, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), type of drug, emerging focus areas and regional distribution of trials.
? A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular publisher and copyright holders.(in terms of number of articles published).
? An in-depth analysis of the patents that have been filed / granted for novel antibody therapies, between 2017- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.
? An analysis of the partnerships that have been established in this domain, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant types of deals.
? An analysis of big pharma players engaged in the field of novel antibody therapies, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indication, number of partnerships, number of patents and years of experience.
? An insightful market forecast analysis, highlighting the future potential of the novel antibody therapies market till the year 2035. It includes future sales projections of novel antibody therapies that are either marketed or are likely to be marketed within the next few years. In order to provide a detailed future outlook, our projections have been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific).

Key Market Companies
? Actinium Pharmaceuticals
? Molecular Templates
? Philogen
? Roche
? Seagen
? Sesen bio
? Telix Pharmaceuticals
? Y-mAbs Therapeutics